The FDA approved an adjuvant combination of pembrolizumab and belzutifan for adults with high-risk clear cell renal cell carcinoma after surgery. The decision follows translational work from Dana-Farber researchers supporting the regimen’s clinical rationale. Pembrolizumab targets immune checkpoints, while belzutifan inhibits HIF-2α, aiming to attack tumor biology through complementary mechanisms in the post-surgical setting. The approval expands the growing role of combination immunotherapy and hypoxia-pathway inhibition beyond advanced disease. For clinicians and developers, the move reinforces the post-op immuno-oncology and biologic target strategy as a regulatory pathway for high-risk RCC—an area with significant unmet need for durable recurrence prevention.